Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

Catarina Maia, Noemi Puig, Cristina Pérez Ruiz, Maria Teresa Cedena Romero, Camila Guerrero, Marta Larrayoz, Cirino Botta, Norma C. Gutierrez, María José Calasanz, Maria Luisa Martin-Ramos, Miguel Hernández, Laura Rosinol Dachs, Esther González Garcia, Felipe De Arriba, Albert Oriol, Veronica Gonzalez-Calle, Fernando Escalante, Javier de la Rubia, Mercedes Gironella Mesa, Rafael Rios, Ricarda Belen Garcia Sanchez, Jose Maria Arguiñano PEREZ, Adrian Alegre, Jesus Martin, María del Carmen Couto Caro, Maria Casanova, Mario Arnao Herraiz, Ernesto Pérez, Sebastián Garzón López, Marta Sonia Gonzalez Perez, Guillermo Martín-Nuñez, Adriana Rossi, Morton Coleman, Cristina Encinas, Ana M. Vale, Ana Isabel Teruel, María Cortés Rodríguez, Jose A. Martinez-Climent, Juan-José Lahuerta, Joan Bladé Creixenti, Ruben Niesvizky, Jesús San-Miguel, Maria-Victoria Mateos, Bruno Paiva

Blood (2022) 140 (Supplement 1): 4200–4203.

https://doi.org/10.1182/blood-2022-163058

Published: 2022

Journal Articles

Long-Term Outcome of Low Dose of Anti-t-Lymphocyte Globulin in the Prophylaxis of Graft-Versus-Host Disease in Unrelated Myeloablative Hematopoietic Stem Cell Transplantation

Juan Manuel Cerezo, Maria Aranzazu Bermudez, David Martin Lorenzana, Sara Fenandez Luis, Lucrecia Yáñez, Mercedes Colorado, Miriam Sánchez Escamilla, Iñigo Romón, Jose Luis Arroyo, Guillermo Martín Sánchez, Enrique M. Ocio

Blood (2022) 140 (Supplement 1): 12871–12873.

https://doi.org/10.1182/blood-2022-169593

Published: 2022

Journal Articles

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial

Noemi Puig, MD PhD, Miguel T Hernández, Laura Rosinol Dachs, Esther González Garcia, MD, Felipe De Arriba, PhD, Albert Oriol, MD, Veronica Gonzalez-Calle, Fernando Escalante, MD, Javier De La Rubia, Mercedes Gironella Meda, Rafael Ríos Tamayo, Ricarda Belen Garcia Sanchez, José María Arguiñano Pérez, MD, Adrián Alegre Amor, MD, Jesús Martín, Norma C. Gutierrez, MD PhD, Maria Jose Calasanz, PhD BSc, Maria Luisa Martin-Ramos, María del Carmen Couto Caro, Maria Casanova, MD, Mario Arnao, MD, Ernesto Pérez Persona, Sebastián Garzón López, Marta Sonia Gonzalez, MD, Guillermo Martín Sánchez, MD, Adriana C. Rossi, MD MSc, Morton Coleman, MD, Cristina Encinas, Ana María Vale López, Ana Isabel Teruel, MDcal Doctor, Bruno Paiva, PhD, Maria Teresa Cedena Romero, MD PhD, Jesús San-Miguel, Juan Jose Lahuerta, MD PhD, Joan Bladé, MD, Ruben Niesvizky, MD, Maria-Victoria Mateos

Blood (2019) 134 (Supplement_1): 694.

https://doi.org/10.1182/blood-2019-123997

Published: 2019

Journal Articles

Retrospective Non-Interventional Assessment of the Use of Idelalisib in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients in Spain

Blood (2019) 134 (Supplement_1): 5473.

https://doi.org/10.1182/blood-2019-126588

Published: 2019

Journal Articles

Risk Adapted Antifungal Strategy in Allogeneic Stem Cell Transplantation. Should We Change the Current Guidelines?

Lucrecia Yanez San Segundo, MD PhD, Noemi Fernandez Escalada, MD, Arancha Bermúdez, MD, Guillermo Martín Sánchez, MD, Sara García Avila, MD, Mónica López Duarte, MD, Mercedes Colorado, MD, Iñigo Romon, MD PhD, Carlos Richard, MD, Enrique M. Ocio, MD PhD

Blood (2019) 134 (Supplement_1): 5655.

https://doi.org/10.1182/blood-2019-130731

Published: 2019

Journal Articles

Genomic Instability and a Preferential Involvement of Ras Pathway in the Myelodysplastic Syndromes Evolution to Secondary Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 3082.

https://doi.org/10.1182/blood-2018-99-118224

Published: 2018

Journal Articles

Very Low Dose of Anti-T-Lymphocyte Globulin Protects Against Severe Forms of Graft Versus Host Disease in High Risk Patients: The Experience in Our Center

Joan Manuel Mora, MD, Arancha Bermúdez, MD, Miguel Angel Cortés, MD, Yolanda González Romero, MD, Mercedes Colorado, MD, Cristina Fernández Martínez, MD, Almudena Cabero Martínez, MD, David Gómez, MD, Sara Fernández Luis, MD, Sara García Ávila, MD, Lucrecia Yáñez, MD PhD, Irati Ormazabal, MD, Guillermo Martín Sánchez, MD, Jose Luis Arroyo, MD, Javier Núñez, MD, Iñigo Romón, MD PhD, Eulogio Conde, MD PhD, Carlos Richard, MD

Blood (2018) 132 (Supplement 1): 5723.

https://doi.org/10.1182/blood-2018-99-118664

Published: 2018

Journal Articles

New Score Prognostic System for Patients with MDS and Intermediate IPSS-R: Novel Algorithm to Distinguish Between Low and High Risk in This Subset of Patients. Results from the Spanish Group of MDS (GESMD). Gesmdi Score

Blood (2016) 128 (22): 4323.

https://doi.org/10.1182/blood.V128.22.4323.4323

Published: 2016

Journal Articles

Efficacy and Safety of a Biosimilar Granulocyte-Colony Stimulating Factor for Stem Cell Mobilization before Autologous Hematopoietic Stem Cell Transplantation

Guillermo Martín-Sánchez, MD, Cristina Amunarriz, MD, Miriam Sanchez, Maria Aranzazu Bermudez, MD, Lucrecia Yañez, MD PhD, Mercedes Colorado, MD, Carlos Richard, MD, Eulogio Conde, MD PhD, Jose Luis Arroyo, MD PhD

Blood (2016) 128 (22): 5737.

https://doi.org/10.1182/blood.V128.22.5737.5737

Published: 2016

Journal Articles

B Cell Lymphoma Unclassifiable, with Features Intermediate Between Diffuse Large B Cell Lymphoma and Burkitt Lymphoma and Diffuse Large B Cell Lymphoma NOS with Doble/Triple Translocations: Immunophenotypic Analysis

Sonia González de Villambrosia, Mercedes Colorado, Andres Insunza, Ana Batlle, Brenda López-Pereira, Guillermo Martin, Paloma Ibarrondo, Santiago Montes-Moreno, Eulogio Conde, MD PhD

Blood (2015) 126 (23): 5037.

https://doi.org/10.1182/blood.V126.23.5037.5037

Published: 2015

Journal Articles

Immunoparesis Recovery As Predictor Marker of Progression after Autologous Stem Cell Transplantation in Multiple Myeloma

Blood (2015) 126 (23): 4356.

https://doi.org/10.1182/blood.V126.23.4356.4356

Published: 2015

Journal Articles

Bence Jones Proteinuria in Smoldering Multiple Myeloma As Predictor Marker of Progression to Symptomatic Multiple Myeloma

Veronica Gonzalez de la Calle, MD, Ramon Garcia-Sanz, Eduardo Sobejano, Enrique M. Ocio, MD PhD, Noemi Puig, MD PhD, Norma Carmen Gutierrez, PhD MD, Alberto Melón, MD, Joaquin Gonzalez, MD, Alfonso Garcia de Coca, MD, Jose M. Hernandez, MD, Roberto Hernandez, MD, Abelardo Barez, MDPhD, Jose M. Alonso, MD, Carmen Aguilera, MD, Fernando Escalante, Guillermo Martin, MD, Rosa Lopez, MD, Pilar de la Fuente, MD, Maria-Victoria Mateos, MD PhD

Blood (2014) 124 (21): 3369.

https://doi.org/10.1182/blood.V124.21.3369.3369

Published: 2014

Journal Articles

Outcome Depend On Age But Not Comorbidity Score, In Patients treated With Fludarabine and Busulfan (FB4) As Conditioning Regimen In Allogeneic Stem Cell Transplantation

Javier Nunez, MD, Arancha Bermudez, MD, Lucrecia Yanez, MD, Guillermo Martin, MD, Andres Insunza, MD, Carlos Richard, MD, Carmen Montes Gaisan, MD, Eulogio Conde, MD, PhD

Blood (2013) 122 (21): 4533.

https://doi.org/10.1182/blood.V122.21.4533.4533

Published: 2013

Journal Articles

Treatment With Leukapheresis In Patients Diagnosed With Hyperleukocytic Acute Myeloid Leukemia

David Martínez-Cuadrón, Pau Montesinos, Federico Moscardo, Lineth Lopez, MD, Guillermo Martin, Pilar Solves, Blanca Boluda, Mariluz Pérez-Sirvent, Belen Vera, Ines Navarro, Carmen M Alonso, Jesus Martinez, MD, Francisca López-Chulia, Jaime Sanz, MD, Nelly Carpio, Rebeca Rodríguez-Veiga, Gloria Iacoboni, Guillermo Sanz, MD, PhD, Miguel Sanz

Blood (2013) 122 (21): 5046.

https://doi.org/10.1182/blood.V122.21.5046.5046

Published: 2013

Journal Articles

Minimal Residual Diease Evaluation By Flow Cytometry Is a Complementary Tool To Cytogenetics For Treatment Decision In Acute Myeloid Leukemia

Blood (2013) 122 (21): 2576.

https://doi.org/10.1182/blood.V122.21.2576.2576

Published: 2013

Journal Articles

Azacitidine As Front-Line Therapy in AML: Results From Spanish National Registry. Alma Study Investigators

Blood (2012) 120 (21): 3593.

https://doi.org/10.1182/blood.V120.21.3593.3593

Published: 2012

Journal Articles

Autologous Stem Cell Transplantation (ASCT) in 121 Acute Myeloid Leukemias (AML): A Single Center Experience From 1988 to 2010

Carmen Montes-Gaisan, MD, Amalia Cuesta, MD, Susana Herraez, MD, German Perez, MD, Guillermo Martin, MD, Arancha Bermudez, MD, Andres Insunza, MD, Carlos Richard, MD, Eulogio Conde, MD, PhD, Arturo Iriondo, MD

Blood (2011) 118 (21): 3099.

https://doi.org/10.1182/blood.V118.21.3099.3099

Published: 2011

Journal Articles

A novel NUP98/RARG gene fusion in acute myeloid leukemia resembling acute promyelocytic leukemia

Esperanza Such, José Cervera, Ana Valencia, Eva Barragán, Mariam Ibañez, Irene Luna, Óscar Fuster, Maria Luz Perez-Sirvent, Leonor Senent, Amparo Sempere, Jesús Martinez, Guillermo Martín-Aragonés, Miguel A. Sanz

Blood (2011) 117 (1): 242–245.

https://doi.org/10.1182/blood-2010-06-291658

Published: 2011

Journal Articles

CD34+ Cell Dose Is the Major Cell Dose Determinant of Myeloid Engraftment After Single Umbilical Cord Blood Transplantation (sUCBT) for Adult Patients with High-Risk Hematologic Malignancies

Jaime Sanz, Pau Montesinos, David Martinez, Ignacio Lorenzo, Javier Palau, Luis Larrea, Dolores Planelles, Guillermo Martin, Isidro Jarque, Javier De La Rubia, Federico Moscardo, Jesus Martinez, Miguel Angel Sanz, Guillermo F Sanz, MD, PhD

Blood (2010) 116 (21): 1339.

https://doi.org/10.1182/blood.V116.21.1339.1339

Published: 2010

Journal Articles

Analysis of Spanish Experience During Imiglucerase Shortage

Pilar Giraldo, PhD, Pilar Irún, PhD, Pilar Alfonso, PhD, Jaime Dalmau, MD, MAngeles Fernández-Galán, MD, Antonio Figueredo, MD, Angela Ibañez, MD, Jesús M Hernández-Rivas, PhD, Elisa Luño, MD, Francisca Marín-Jimenez, Guillermo Martin-Nuñez, MD, Jorge Montserrat, MD, Javier De la Serna, MD, PhD, Lucia Villalon, MD, Miguel Pocovi, PhD

Blood (2010) 116 (21): 4725.

https://doi.org/10.1182/blood.V116.21.4725.4725

Published: 2010

NARROW

Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

Long-Term Outcome of Low Dose of Anti-t-Lymphocyte Globulin in the Prophylaxis of Graft-Versus-Host Disease in Unrelated Myeloablative Hematopoietic Stem Cell Transplantation

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial

Retrospective Non-Interventional Assessment of the Use of Idelalisib in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients in Spain

Risk Adapted Antifungal Strategy in Allogeneic Stem Cell Transplantation. Should We Change the Current Guidelines?

Genomic Instability and a Preferential Involvement of Ras Pathway in the Myelodysplastic Syndromes Evolution to Secondary Acute Myeloid Leukemia

Very Low Dose of Anti-T-Lymphocyte Globulin Protects Against Severe Forms of Graft Versus Host Disease in High Risk Patients: The Experience in Our Center

New Score Prognostic System for Patients with MDS and Intermediate IPSS-R: Novel Algorithm to Distinguish Between Low and High Risk in This Subset of Patients. Results from the Spanish Group of MDS (GESMD). Gesmdi Score

Efficacy and Safety of a Biosimilar Granulocyte-Colony Stimulating Factor for Stem Cell Mobilization before Autologous Hematopoietic Stem Cell Transplantation

B Cell Lymphoma Unclassifiable, with Features Intermediate Between Diffuse Large B Cell Lymphoma and Burkitt Lymphoma and Diffuse Large B Cell Lymphoma NOS with Doble/Triple Translocations: Immunophenotypic Analysis

Immunoparesis Recovery As Predictor Marker of Progression after Autologous Stem Cell Transplantation in Multiple Myeloma

Bence Jones Proteinuria in Smoldering Multiple Myeloma As Predictor Marker of Progression to Symptomatic Multiple Myeloma

Outcome Depend On Age But Not Comorbidity Score, In Patients treated With Fludarabine and Busulfan (FB4) As Conditioning Regimen In Allogeneic Stem Cell Transplantation

Treatment With Leukapheresis In Patients Diagnosed With Hyperleukocytic Acute Myeloid Leukemia

Minimal Residual Diease Evaluation By Flow Cytometry Is a Complementary Tool To Cytogenetics For Treatment Decision In Acute Myeloid Leukemia

Azacitidine As Front-Line Therapy in AML: Results From Spanish National Registry. Alma Study Investigators

Autologous Stem Cell Transplantation (ASCT) in 121 Acute Myeloid Leukemias (AML): A Single Center Experience From 1988 to 2010

A novel NUP98/RARG gene fusion in acute myeloid leukemia resembling acute promyelocytic leukemia

CD34+ Cell Dose Is the Major Cell Dose Determinant of Myeloid Engraftment After Single Umbilical Cord Blood Transplantation (sUCBT) for Adult Patients with High-Risk Hematologic Malignancies

Analysis of Spanish Experience During Imiglucerase Shortage

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only